A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
2024; Elsevier BV; Linguagem: Inglês
10.1016/j.annonc.2024.08.2343
ISSN1569-8041
AutoresJean‐Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard, A. Italiano, Armelle Dufresne, Séverine Metzger, Sylvie Chabaud, David Pérol, A. Le Cesne,
Tópico(s)Soft tissue tumors and treatment
ResumoThe administration of adjuvant imatinib during 3 years is indicated after resection of primary localized GIST at high risk of recurrence, but many patients relapse afterwards.
Referência(s)